Summary

2.00 0.03(1.52%)11/19/2024
Inhibikase Therapeutics Inc (IKT)

Key Facts


Historical Returns
1 Day1 Week1 Month3 Months6 Months1 Year5 YearsAll Time
1.52-28.88-10.4551.547.65128.940.00-80.10


Price Chart Compare
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1

Earnings
  • IKT reported last earnings on 2024-08-14 after the market.
  • An EPS of $-0.66 was observed compared to an estimated EPS of $-0.58, resulting in a surprise value of $-0.08.
  • A revenue of $0 million was observed compared to an estimated revenue of $0 million, resulting in a surprise value of $0 Million.


    • Fundamental Ratings
    CategoryRating
    Main RatingC+
    Recommended RatingSell
    DCFNeutral
    ROEStrong Buy
    ROAStrong Sell
    Debt/EquityStrong Sell
    P/EStrong Sell
    P/BStrong Sell


    Key Statistics
    Trading Data
    Close2.00
    Open1.96
    High2.05
    Low1.92
    Volume155,275
    Change0.03
    Change %1.52
    Avg Volume (20 Days)334,281
    Volume/Avg Volume (20 Days) Ratio0.46
    52 Week Range0.80 - 3.82
    Price vs 52 Week High-47.64%
    Price vs 52 Week Low150.00%
    Range-4.83
    Gap Up/Down-0.28
    Fundamentals
    Market Capitalization (Mln)19
    EBIDTA0
    PE Ratio0.0000
    PEG Ratio0.0000
    WallStreet Target Price13.50
    Book Value1.7160
    Earnings Per Share-0.7840
    EPS Estimate Current Quarter-0.1400
    EPS Estimate Next Quarter-0.1500
    EPS Estimate Current Year-0.7800
    EPS Estimate Next Year-0.6100
    Diluted EPS (TTM)-0.7840
    Revenues
    Profit Marging0.0000
    Operating Marging (TTM)-3.3421
    Return on asset (TTM)-0.2885
    Return on equity (TTM)-0.5759
    Revenue TTM3,269,077
    Revenue per share TTM0.2340
    Quarterly Revenue Growth (YOY)7.7170
    Quarterly Earnings Growth (YOY)0.0000
    Gross Profit (TTM)-195,334
    Dividends
    Dividend Share0.0000
    Dividend Yield
    Valuations
    Trailing PE0.0000
    Forward PE0.0000
    Price Sales (TTM)0.0000
    Price Book (MRQ)0.9733
    Revenue Enterprise Value 2.7480
    EBITDA Enterprise Value0.2369
    Shares
    Shares Outstanding25,155,200
    Shares Float18,329,083
    Shares Short0
    Shares Short (Prior Month)0
    Shares Ratio0.00
    Short Outstanding (%)0.00
    Short Float (%)0.00
    Insider (%)21.22
    Institutions (%)28.05


    News
    11/19 13:32 EST - seekingalpha.com
    Inhibikase: Potential To Improve Current Treatment Options For PAH Patients
    The company received FDA approval to initiate a late-stage study of IKT-001Pro for pulmonary arterial hypertension, backed by $275 million in funding. IKT-001Pro, a modified version of imatinib, aims to treat PAH with fewer side effects, leveraging Inhibikase's RAMP drug innovation engine....
    11/14 08:37 EST - globenewswire.com
    Inhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Activity
    -- Transformative Financing worth up to $275 million from Top-Tier Institutional Healthcare Investors -- -- Advancement of IkT-001Pro into a Late-Stage Clinical Trial Program in Pulmonary Arterial Hypertension --
    10/21 09:05 EST - globenewswire.com
    Inhibikase Therapeutics Announces Closing of up to $275 Million Financing and Advancement of IkT-001Pro into a Late Stage Clinical Trial in Pulmonary Arterial Hypertension
    -- IkT-001Pro to be developed as a New Molecular Entity as the first oral, potentially disease-modifying treatment for a rapidly fatal disease primarily afflicting women between the ages of 30 and 60 -- BOSTON and ATLANTA, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq:...
    10/09 09:18 EST - globenewswire.com
    Inhibikase Therapeutics Announces Pricing of $110 Million Private Placement to Advance IkT-001Pro, an Optimized Prodrug of Imatinib, into a Late-Stage Trial in Pulmonary Arterial Hypertension
    -- Aggregate investment of up to approximately $275 Million by healthcare-focused investment funds, led by Soleus Capital -- BOSTON and ATLANTA, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or the “Company”), a clinical-stage pharmaceutical...
    08/15 18:13 EST - seekingalpha.com
    Inhibikase Therapeutics, Inc. (IKT) Q2 2024 Earnings Call Transcript
    Inhibikase Therapeutics, Inc. (NASDAQ:IKT ) Q2 2024 Earnings Conference Call August 15, 2024 8:00 AM ET Company Participants Alexander Lobo - Precision AQ, Investor Relations Milton Werner - President and Chief Executive Officer Garth Lees-Rolfe - Chief Financial Officer Conference Call...
    08/14 16:25 EST - globenewswire.com
    Inhibikase Therapeutics Reports Second Quarter Financial Results and Highlights Recent Period Activity
    BOSTON and ATLANTA, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease ("PD"), Parkinson's-related disorders and...
    08/07 08:00 EST - globenewswire.com
    Inhibikase Therapeutics to Report Second Quarter 2024 Financial Results on August 14, 2024
    BOSTON and ATLANTA, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease, Parkinson's-related disorders...
    06/17 08:05 EST - globenewswire.com
    Inhibikase Therapeutics Completes Enrollment of the Phase 2 ‘201' Trial Evaluating Risvodetinib in Untreated Parkinson's Disease
    BOSTON and ATLANTA, June 17, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease, Parkinson's-related disorders...
    06/05 08:05 EST - globenewswire.com
    Inhibikase Therapeutics Announces Expansion to its Therapeutic Pipeline and Updates its Research and Development Programs
    - Company positioning multiple assets for late-stage development across its therapeutic pipeline – BOSTON and ATLANTA, June 05, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing protein kinase inhibitor...
    05/20 08:01 EST - globenewswire.com
    Inhibikase Therapeutics Announces Pricing of Registered Direct Offering and Warrant Inducement, Priced At-The-Market for Aggregate Gross Proceeds of $4.0 Million
    BOSTON and ATLANTA, May 20, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease, Parkinson's-related disorders...
    05/17 21:57 EST - seekingalpha.com
    Inhibikase Therapeutics, Inc. (IKT) Q1 2024 Earnings Call Transcript
    Inhibikase Therapeutics, Inc. (NASDAQ:IKT ) Q1 2024 Earnings Conference Call May 16, 2024 8:00 AM ET Company Participants Alexander Lobo - Stern Investor Relations Milton Werner - CEO Garth Lees-Rolfe - CFO Conference Call Participants Ed White - H.C. Wainwright Operator Greetings and welcome to...
    05/15 20:00 EST - globenewswire.com
    Inhibikase Therapeutics Reports First Quarter Financial Results and Highlights Recent Period Activity
    Company to host conference call on Thursday, May 16, 2024 at 8:00 a.m. ET Company to host conference call on Thursday, May 16, 2024 at 8:00 a.m. ET
    05/15 08:45 EST - globenewswire.com
    Inhibikase Therapeutics Announces Request for Withdrawal of S-1 Registration Statement
    BOSTON and ATLANTA, May 15, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease, Parkinson's-related disorders...
    05/09 08:00 EST - globenewswire.com
    Inhibikase Therapeutics Announces Final Pre-IND Meeting Outcomes for IkT-001Pro as a Treatment for Pulmonary Arterial Hypertension
    - FDA indicated IkT-001Pro can be considered a New Molecular Entity and is eligible for exclusivity designations in Pulmonary Arterial Hypertension –
    04/18 16:30 EST - globenewswire.com
    Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs
    BOSTON and ATLANTA, April 18, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease ("PD"), Parkinson's-related disorders and...
    04/03 08:05 EST - globenewswire.com
    Inhibikase Therapeutics Announces Pre-IND Meeting with the FDA for IkT-001Pro in Pulmonary Arterial Hypertension
    Meeting to discuss potential of IkT-001Pro as a disease modifying treatment for Pulmonary Arterial Hypertension Meeting to discuss potential of IkT-001Pro as a disease modifying treatment for Pulmonary Arterial Hypertension
    03/28 17:13 EST - seekingalpha.com
    Inhibikase Therapeutics, Inc. (IKT) Q4 2023 Earnings Call Transcript
    Inhibikase Therapeutics, Inc. (IKT) Q4 2023 Earnings Call Transcript
    03/27 16:15 EST - globenewswire.com
    Inhibikase Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Activity
    Company to host conference call on Thursday, March 28, 2024 at 8:00 a.m. ET Company to host conference call on Thursday, March 28, 2024 at 8:00 a.m. ET
    03/07 08:30 EST - globenewswire.com
    Inhibikase Therapeutics to Provide Trial Update for Risvodetinib at the 2024 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders
    BOSTON and ATLANTA, March 07, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease, Parkinson's-related disorders...
    02/28 16:05 EST - globenewswire.com
    Inhibikase Therapeutics Announces Full Outcomes of its Pre-NDA Meeting with the FDA for IkT-001Pro
    Company to pursue eleven indications for IkT-001Pro; all previously approved for treatment with imatinib mesylate Company to pursue eleven indications for IkT-001Pro; all previously approved for treatment with imatinib mesylate